Isomorphic Labs , the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereig…
Why this update matters
This developing story is relevant for readers tracking technology because it reflects fresh changes from the original source and signals where attention is shifting next.
Key details
The report was collected automatically and prepared for publication with a newsroom workflow that focuses on clarity, search visibility, and quick understanding.
Readers should review the original source for direct statements, official notices, and any later corrections or additions as the story evolves.
Related coverage
Continue reading with more reporting from the same topic cluster.